EpimAb is a China-based clinical stage biotech company specializing in bispecific antibody development.
Member count: 11-50
Total raised: $219M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
Funding Rounds 3
| Date | Series | Amount | Investors | Deal News |
| 05.06.2019 | Series B | $74M | - | finsmes.co... |
| 25.04.2017 | Series A | $25M | - | finsmes.co... |
| - | Series C | $120M | - | oaoa.com/n... |
Mentions in press and media 6
| Date | Title | Description | Category | Author | Source |
| 06.06.2019 | Fitness St... | THE CLIMB TO IPO Peloton, the... | - | - | fortune.co... |
| 05.06.2019 | EpimAb Bio... | EpimAb Biotherapeutics, a Shan... | China | - | finsmes.co... |
| 25.04.2017 | Term Sheet... | MONEY-LOSING HOUSE OF HORRORS ... | - | - | fortune.co... |
| 25.04.2017 | EpimAb Bio... | EpimAb Biotherapeutics, a Shan... | China | - | finsmes.co... |
| 11.10.2016 | Kymab sign... | Kymab signs bispecific antibod... | - | - | cambridgen... |
| - | EpimAb Bio... | SHANGHAI--(BUSINESS WIRE)--Mar... | - | - | oaoa.com/n... |